In this study, we assessed the constitutive PD-L1 expression as well as the cellular distribution of ER-positive/Her2-negative, ER/Her2-double-positive, and triple-negative breast cancer (BC) cell lines under standardized conditions in vitro and as a function of cytotoxic treatments. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.